The right structure

Cytokinetics Inc. could get $125 million from Amgen Inc. before the latter even touches CYTK's CK-1827452, a cardiac myosin activator that has completed two Phase I studies in heart failure. But what CYTK President Robert Blum likes most about the deal is the structure of the co-promotion rights.

AMGN (Thousand Oaks, Calif.) paid CYTK

Read the full 534 word article

How to gain access

Continue reading with a
two-week free trial.